NDA 021337 · Msd Sub Merck
Invanz
Ertapenem Sodium · Intramuscular, Intravenous
NovelLast checked: Nov 20, 2026Latest source record: Mar 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Nov 21, 2001
Approved uses
4
Original approval plus efficacy supplements
Registered trials
76
28 Phase 3, 6 recruiting
FAERS reports
7,465
6,366 serious, 639 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. ( 1.1 ) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) Community-acquired pneumonia. ( 1.3 ) Complicated urinary tract infections including pyelonephritis. ( 1.4 ) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ertapenem for injection and other antibacterial drugs, ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) 1.1 Complicated Intra-Abdominal Infections Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli , Clostridium clostridioforme , Eubacterium lentum , Peptostreptococcus species, Bacteroides fragilis , Bacteroides distasonis , Bacteroides ovatus , Bacteroides thetaiotaomicron , or Bacteroides uniformis . 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis Ertapenem for injection is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections,...
Mechanism: Ertapenem sodium is a carbapenem antibiotic [see Clinical Pharmacology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 10, 2006 Supplement 21 · Efficacy LabelReviewLetter
- Oct 14, 2005 Supplement 19 · Efficacy LabelLetter
- May 18, 2005 Supplement 18 · Efficacy · priority review LabelLetter
- Nov 21, 2001 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Medical ReviewPediatric Written Request
1 products under this application
- INVANZ · ERTAPENEM SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INTRAMUSCULAR, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ertapenem" as an intervention, any sponsor and status, largest first.
- Combination Antibiotic Therapy for Staphylococcus Aureus BacteremiaPivotal-lookingRecruiting
Intermountain Health Care, Inc.Academic, hospital or other
NCT07376889 · 2,096 participants (planned) · Start Feb 1, 2026 · Primary completion Jan 2029
Drug: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Brighton, Colorado; Denver, Colorado; Grand Junction, Colorado · 13 sites in all
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in AdultsPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03357614 · 1,395 participants · Start Sep 18, 2018 · Primary completion Dec 14, 2019
Drug: Sulopenem; Sulopenem-Etzadroxil/Probenecid and 3 more · For: Complicated Urinary Tract Infections
Sites: Bellflower, California; Chula Vista, California; La Mesa, California · 32 sites in all
Spero TherapeuticsIndustry
NCT03788967 · 1,372 participants · Start Jun 3, 2019 · Primary completion May 20, 2020
Drug: TBPM-PI-HBr; Ertapenem and 2 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
Sites: La Mesa, California; Miami, Florida; Blagoevgrad, Bulgaria · 96 sites in all
- Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract InfectionsPivotal-lookingCompleted
Tetraphase Pharmaceuticals, IncIndustry
NCT03032510 · 1,205 participants · Start Jan 2017 · Primary completion Dec 2017
Drug: Eravacycline; Ertapenem and 2 more · For: Complicated Urinary Tract Infections
Sites: Fullerton, California; Los Angeles, California; Torrance, California · 69 sites in all
- Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.Pivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00366249 · 1,061 participants · Start Jan 2007 · Primary completion Mar 2009
Drug: Tigecycline; Ertapenem · For: Bacterial Infections; Diabetic Foot; Osteomyelitis
Sites: Los Angeles, California; Northridge, California; San Francisco, California · 211 sites in all
- A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00090272 · 952 participants · Start Apr 2002 · Primary completion Mar 2005
Drug: MK0826, ertapenem sodium; Comparator: cefotetan · For: Colorectal Surgery
- Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or ErtapenemPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00492726 · 804 participants · Start Jul 2006 · Primary completion Feb 2009
Drug: Moxifloxacin (Avelox, BAY12-8039); Ertapenem intravenous · For: Infection
Sites: Ciudadela, Argentina; De Febrero 3, Argentina; Merlo, Argentina · 52 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,161
- macular degeneration808
- off label use539
- pyrexia467
- confusional state441
- product use in unapproved indication434
- nausea397
- pain345
- weight decreased274
- malaise271
- anaemia268
- hallucination266
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 60 |
| 2006 | 93 |
| 2007 | 117 |
| 2008 | 125 |
| 2009 | 103 |
| 2010 | 117 |
| 2011 | 138 |
| 2012 | 246 |
| 2013 | 287 |
| 2014 | 279 |
| 2015 | 347 |
| 2016 | 318 |
| 2017 | 284 |
| 2018 | 425 |
| 2019 | 429 |
| 2020 | 483 |
| 2021 | 768 |
| 2022 | 633 |
| 2023 | 585 |
| 2024 | 589 |
| 2025 | 538 |
| 2026 | 386 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Invanz (Ertapenem Sodium)
2024 spending
$11K
Beneficiaries
26
34 claims
Per beneficiary
$415
$46.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $463,297 |
| 2021 | $187,177 |
| 2022 | $96,539 |
| 2023 | $13,802 |
| 2024 | $10,795 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial.
Salminen P, Salminen R, Kallio J, et al. · JAMA 2026 · Comparative Study, Multicenter Study
- Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Eckburg PB, Muir L, Critchley IA, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis: The APPAC Randomized Clinical Trial.
Salminen P, Paajanen H, Rautio T, et al. · JAMA 2015 · Comparative Study, Multicenter Study
- The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, et al. · J Antimicrob Chemother 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis.
Beig M, Aghamohammad S, Majidzadeh N, et al. · J Glob Antimicrob Resist 2024 · Meta-Analysis, Systematic Review
- Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, et al. · JAMA Netw Open 2022 · Multicenter Study, Randomized Controlled Trial
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.